Jonathan Hernandez Texas Rangers #72 Relief Pitcher Follow HT/WT 6' 2", 175 lbs DOB 7/6/1996 (24) BAT/THR Right/Right Birthplace Memphis, TN Status Active 2020 season stats SV 0 … Anderson Cancer Center, University at Buffalo Department of Surgery General Surgery Residency, Metastatic Colorectal Cancer: Clinical Trial Conversation, U.S. Department of Health and Human Services     |     National Institutes of Health     |     National Cancer Institute     |     USA.gov, Home  |  Contact  |  Policies  |  Accessibility  |  Viewing Files  |  FOIA, Associate Professor of Surgery, Uniformed Services University of the Health Sciences, Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D. Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG. Dr. Hernandez’s research program focuses on interrogating the molecular underpinnings of metastatic colonization in order to interrupt the process prior to its completion.

The bounds of these perfusion systems have, however, not been tested or optimized for longer than 6 hours at normothermic temperature.


The webinar, “Navigating New Treatment Options for Gastric Cancer: Reaching above and beyond the standard of care,” was facilitated by the NIH Clinical Center and Inspire, a social network for health that connects patients and caregivers in a safe, permission-based manner. When David Fogel had a stomach, his fast-paced life was focused on expanding Bump 'n Grind, his coffee shop and record store in downtown Silver Spring, and managing a creative agency and two co-working spaces. The reasons for the inadequacies of these model systems, which are largely based upon cell lines, mouse models, or patient-derived xenografts, are myriad, but are almost certainly related to the absence of the human stromal component and its intricate relationship with tumor cells. placement of additional sensors for increased real-time hemodynamic and biochemical analysis.

Read more... On Wednesday, Nov. 29, 2017, NIH Foregut Team members presented information and answered questions during a webinar on stomach cancer treatment options. We would like to emphasize that it is not our intention to take over your care from your primary physician. For patients undergoing resection, identifying and targeting the mechanisms that support the survival and outgrowth of latent, disseminated tumor cells holds great promise for the prevention of tumor recurrence. The data that we obtain from these clinics will help us to design innovative treatment protocols.

Our interpretation is that the currently available model systems lack the appropriate clinical predictive power. Using existing treatment protocols at the NIH Clinical Center, we have already begun optimizing the system for use on tumor-bearing liver segments that are removed as part of standard treatment algorithms. Chief of Surgical Oncology Section. Most other studies are clinical trials, which often are the first tests of new drugs and therapies in people. A summer student will work with our multi-disciplinary team to further optimize the perfusion machines with. Modeling the multi-faceted interactions between human cancer cells and the multitude of various stromal components, including activated fibroblasts, immune cell infiltrate, and the abnormal vasculature is, at present, an impossibility. Physician-Scientist Early Investigator Pediatric Oncology Branch christine.heske@nih.gov View My Team Stephen M. Hewitt, M.D., Ph.D. Defining optimum treatment of patients with pancreatic adenocarcinoma using regret-based decision curve analysis. National Institute of Biomedical Imaging and Bioengineering (NIBIB). To make an in-person or virtual appointment with our team please call 240-858-3610 or email Surgical.Oncology@nih.gov. You will be seen by the National Cancer Institute experts in cancers of the gastrointestinal tract, (GE junction, stomach, liver, pancreas, bile duct and colon/rectum). The bounds of these perfusion systems have recently been optimized and used to maintain whole human liver viable for one week. PubMed PMID: 31749079.

A summer student will work on further optimization of this model, with the specific focus determined by the project needs and student interest. Dr. Hernandez graduated from medical school with honors from the University of Florida, and completed general surgery training at the University of South Florida. Bethesda, MD 20892, Exvivo Human Tissue Model: Hernandez Lab Research Interests. Moreover, the perfusate is amenable to continuous sampling such that biomarker discovery will be greatly facilitated, with correlations actually relatable to real-time tumor obtained by biopsy. to be better equipped to treat your cancer if it recurs. We can envision a fundamental alteration in drug development such that efficacy is evaluated first, rather than last, with subsequent efforts focused on delivery techniques and minimization of toxicity.

Our lab is exploring the use of these organ perfusion systems to create a new tumor model of the human liver as a site of metastatic disease. The clinical trials at the NIH Clinical Center are predominantly Phase I and Phase II, often first-in-human to test safety and efficacy. U.S. Department of Health and Human Services     |     National Institutes of Health     |     National Cancer Institute     |     USA.gov, Home  |  Contact  |  Policies  |  Accessibility  |  Viewing Files  |  FOIA, Life without a stomach:  a patient's perspective on preventative surgery, advancing stomach cancer research, Thoracic and Gastrointestinal Oncology Branch, U.S. Department of Health and Human Services. Through working closely with the interdisciplinary team, the BESIP intern will gain valuable hands-on experience with multiple procedures and technologies and can expect to gain experience in various areas of cancer and biomedical research. Groh EM, Gupta S, Brown ZJ, Enewold L, Gamble LA, Hernandez JM, Davis JL. However, the number of experts from different fields who are thinking about the specifics of your medical history may allow us to make recommendations to your treating physician, with the goal of improving your health. Alter Wins Nobel Prize Dr. Harvey J. During his fellowships, Dr. Hernandez spent an additional two years in dedicated basic research studying metastatic colonization as a scholar in the Cell Biology Program of the Sloan Kettering Institute supported by NIH funding and a grant from America’s HepatoPancreatoBiliary Association. We use the tumors removed during surgery in our novel ex vivo systems, which allow us to keep your tumor alive for several days. jonathan.hernandez@nih.gov View My Team Christine M. Heske, M.D. COVID-19 is an emerging, rapidly evolving situation.